UnknownNot Applicable

Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit

France300 participantsStarted 2021-11-15

Plain-language summary

In the context of postoperative hypertension in the intensive care units, or after resusitation of hypertensive patients, intravenous antihypertensive drugs are often used. Among those drugs, Nicardipine is an effective drug, but with side effects such as inhibition of pulmonary vasoconstriction. Only preclinical studies have investigated the pathophysiology of this mechanism, and no clinical study have proven its clinical relevance. The aim of this study is to establish the incidence of Nicardipine induced hypoxemia and to compare it to another antihypertensive agent, Urapidil.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Major patient * With acute arterial systolic hypertension over 140mmHg * Requiring intravenous administration of one of the two following drugs : Urapidil or Nicardipine Exclusion Criteria: * Patient ventilated Under Nitrogen Monoxyde * Contraindication to Nicardipine or Urapidil * Refusal of the patient or his relatives * Patient treated for pulmonary hypertension

What they're measuring

Hypoxemia

Timeframe: During the twelve hours following start of drug infusion

Trial details

NCT IDNCT05155202

SponsorUniversity Hospital, Caen

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-11-15

View on ClinicalTrials.gov More Hypoxemic Respiratory Failure trials